English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

SPARC  is a matricellular protein, which, along with other extracellular matrix components including collagens, is commonly over-expressed in fibrotic diseases. The purpose of this study was to examine whether inhibition of  SPARC  can regulate collagen expression  in vitro  and  in vivo , and subsequently attenuate fibrotic stimulation by bleomycin in mouse skin and lungs.    Methods  In  in vitro  studies, skin fibroblasts obtained from a Tgfbr1 knock-in mouse (TBR1 CA ; Cre-ER) were transfected with  SPARC  siRNA. Gene and protein expressions of the Col1a2 and the Ctgf were examined by real-time RT-PCR and Western blotting, respectively. In  in vivo  studies, C57BL/6 mice were induced for skin and lung fibrosis by bleomycin and followed by  SPARC  siRNA treatment through subcutaneous injection and intratracheal instillation, respectively. The pathological changes of skin and lungs were assessed by hematoxylin and eosin and Masson's trichrome stains. The expression changes of collagen in the tissues were assessed by real-time RT-PCR and non-crosslinked fibrillar collagen content assays.    Results   SPARC  siRNA significantly reduced gene and protein expression of collagen type 1 in fibroblasts obtained from the TBR1 CA ; Cre-ER mouse that was induced for constitutively active TGF-β receptor I. Skin and lung fibrosis induced by bleomycin was markedly reduced by treatment with  SPARC  siRNA. The anti-fibrotic effect of  SPARC  siRNA  in vivo  was accompanied by an inhibition of Ctgf expression in these same tissues.    Conclusions  Specific inhibition of  SPARC  effectively reduced fibrotic changes  in vitro  and  in vivo . SPARC inhibition may represent a potential therapeutic approach to fibrotic diseases.

Attenuation of fibrosis in vitro and in vivo with SPARC siRNA